ANTENGENE CORP. DL-0001 (F:722) — Market Cap & Net Worth
Market Cap & Net Worth: ANTENGENE CORP. DL-0001 (722)
ANTENGENE CORP. DL-0001 (F:722) has a market capitalization of $267.00 Million (€228.38 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #15438 globally and #1486 in its home market, demonstrating a -14.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANTENGENE CORP. DL-0001's stock price €0.53 by its total outstanding shares 610925912 (610.93 Million).
ANTENGENE CORP. DL-0001 Market Cap History: 2021 to 2026
ANTENGENE CORP. DL-0001's market capitalization history from 2021 to 2026. Data shows change from $764.23 Million to $378.55 Million (-20.89% CAGR).
ANTENGENE CORP. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANTENGENE CORP. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 722 by Market Capitalization
Companies near ANTENGENE CORP. DL-0001 in the global market cap rankings as of May 5, 2026.
Key companies related to ANTENGENE CORP. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ANTENGENE CORP. DL-0001 Historical Marketcap From 2021 to 2026
Between 2021 and today, ANTENGENE CORP. DL-0001's market cap moved from $764.23 Million to $ 378.55 Million, with a yearly change of -20.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €378.55 Million | +33.84% |
| 2025 | €282.84 Million | +518.75% |
| 2024 | €45.71 Million | -68.93% |
| 2023 | €147.13 Million | -65.67% |
| 2022 | €428.54 Million | -43.93% |
| 2021 | €764.23 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of ANTENGENE CORP. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $267.00 Million USD |
| MoneyControl | $267.00 Million USD |
| MarketWatch | $267.00 Million USD |
| marketcap.company | $267.00 Million USD |
| Reuters | $267.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more